18 F-SynVesT-1 PET in Focal Cortical Dysplasia Type II With Thickening Cortex.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
pubmed:
7
4
2022
medline:
12
7
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
A case of 2-year-old girl with intractable seizures underwent 18 F-FDG PET and MRI for seizure focus localization. MRI demonstrated cortical thickening and blurring of the gray-white matter interface in the right postcentral gyrus with focal hypometabolism in 18 F-FDG PET. The patient subsequently was enrolled in clinical trial of 18 F-SynVesT-1 PET study in epilepsy; a more restricted area of reduced 18 F-SynVesT-1 uptake was noted in the thickened postcentral gyrus. The surgical limits of resection were defined based on ictal semiology, electroencephalography, and imagings. The patient is seizure-free after epilepsy surgery, with histopathology of focal cortical dysplasia type IIb.
Identifiants
pubmed: 35384870
doi: 10.1097/RLU.0000000000004214
pii: 00003072-202208000-00020
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-743Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest: none declared.
Références
Sisodiya SM, Fauser S, Cross JH, et al. Focal cortical dysplasia type II: biological features and clinical perspectives. Lancet Neurol . 2009;8:830–843.
Li S, Cai Z, Wu X, et al. Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem Neurosci . 2019;10:1544–1554.
Li S, Naganawa M, Pracitto R, et al. Assessment of test-retest reproducibility of [ 18 F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol Imaging . 2021;48:1327–1338.
Naganawa M, Li S, Nabulsi N, et al. First-in-human evaluation of 18 F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med . 2021;62:561–567.
Bast T, Ramantani G, Seitz A, et al. Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults. Acta Neurol Scand . 2006;113:72–81.
Najm IM, Sarnat HB, Blumcke I. Review: the international consensus classification of focal cortical dysplasia—a critical update 2018. Neuropathol Appl Neurobiol . 2018;44:18–31.
Maynard LM, Leach JL, Horn PS, et al. Epilepsy prevalence and severity predictors in MRI-identified focal cortical dysplasia. Epilepsy Res . 2017;132:41–49.
Chassoux F, Rodrigo S, Semah F, et al. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology . 2010;75:2168–2175.
Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfan BV, et al. Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci . 2013;38:3529–3539.
Mao C, Jin L, Dou W, et al. Type IIB focal cortical dysplasia with balloon cells in medial temporal lobe epilepsy: clinical, neuroimaging, and histopathological findings. Epilepsy Res . 2019;157:106189.
Finnema SJ, Toyonaga T, Detyniecki K, et al. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [ 11 C]UCB-J positron emission tomography study. Epilepsia . 2020;61:2183–2193.